Cannabis Law Report

JULY 7, 2021

We remain encouraged as we continue our evaluations of MYMD-1 for efficacy and safety – especially as studies continue to suggest we may be able to address many of the concerns that are associated with the current drugs on the market today in these disease areas.”. Media Contact: Will Johnson. Investor Contact: Robert Schatz.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Cannabis Law Report

OCTOBER 15, 2021

At Kidney Week 2021, Goldfinch Bio will present multiple e-posters, including: The design of TRACTION-2, the ongoing Phase 2 clinical trial evaluating GFB-887 for the treatment of focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN). Media: Liz Melone. Date and Time: Tuesday, October 19 th at 5:00 PM ET.

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

Cannabis Law Report

JANUARY 24, 2022

Accomplished leader to oversee Goldfinch Bio’s clinical function to advance precision medicines for people living with kidney disease. Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. Media: Liz Melone. CAMBRIDGE, Mass.–(BUSINESS

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

DECEMBER 26, 2021

EBRX-101 on Track to Submit Regulatory Package for Human DMT Clinical Trial. The Company is pleased to confirm that it is on track to submit its regulatory package to the Dutch ethics committee in early 2022 for its upcoming human trial. For more information, please contact the Company at: Entheon Biomedical Corp.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Miss Marijuana

JUNE 30, 2019

I mean duh, with social media, bosses that don’t understand you have a life and the new Bob Dylan documentary on Netflix – how can anyone doze off and dream anymore? RELATED: I’m A Business Owner Who Uses Cannabis & CBD For Anxiety. Did you know sleep deficiency is a pretty common health issue in the United States?

Sleep 72

Sleep CBD Clinical Trials Oil 72

Cannabis Law Report

JULY 8, 2021

Following the execution of this work, cbdMD Therapeutics will perform the requisite toxicological studies with Ion Tox, a leading in vitro toxicology and ADME-PK testing company, to support the safety of the cannabinoids of interest. and are difficult to predict. cbdMD, Inc. John Weston. Director of Investor Relations.

Research and Development 111

Research and Development Pets Cannabinoids eCommerce 111

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. Mitchell et al., Divito & Robert F. 11 × 11. Feduccia et al.,

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

JANUARY 13, 2020

Continue to explore CBDV in autism through a combination of open-label and investigator-led placebo controlled clinical trials with data from one or more of these programs in 2020. Execute NHIE clinical program utilizing an intravenous formulation of cannabidiol. Media Enquiries: Sam Brown Inc. media enquiries.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

The Blunt Truth

AUGUST 13, 2019

On May 31, 2019, the FDA’s Working Group held a public hearing for stakeholders to share their experiences and challenges with CBD products, including information and views related to product safety. The public hearing attracted over 100 speakers and 2000 participants. Under section 331(ll) of the FD&C Act (21 U.S.C.

CBD 80

CBD Food Seed-To-Sale Wellness and Beauty 80

Cannabis Law Report

OCTOBER 29, 2021

The highlights for the quarter are: As previously disclosed, on September 7, 2021, the Company announced the completion of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”) based investigational new drug, IGC-AD1, intended to alleviate certain symptoms of individuals who have Alzheimer’s disease.

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Cannabis Law Report

JULY 23, 2019

This is particularly the case for cannabis and cannabidiol (CBD) products. As an example, the USPTO allows patents for cannabis inventions but prohibits registering trademarks for cannabis and cannabis products. Koi CBD, LLC is a cannabis company based in California. Laws on Legalised Cannabis.

Law 40

Law Clinical Trials CBD Edibles 40

The Joint Blog

JULY 25, 2020

Cannabis has come a long way from being the taboo herb of decades past. Lately, CBD has warranted a huge share of public and media attention for its perceived benefits to health and well-being. CBD is everywhere these days. CBD is found to be generally safe when consumed in prescribed portions. It has been predicted that the U.S

CBD 33

CBD Clinical Trials Safety Media 33

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. Doctors can prescribe Epidyolex – an oral solution of cannabidiol, which comes from the cannabis plant – if they think it will help sufferers. What is Epidyolex?

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

JANUARY 11, 2019

Thus, the law permits a wide range of dietary ingredients in dietary supplements, including CBDwhich is an extract of a botanical ( Cannabis sativa L. Food and supplements that contain hemp-derived CBD are subject to a comprehensive regulatory framework that addresses both the safety and quality of these products.

Hemp 49

Hemp CBD Law Seed-To-Sale 49

Cannabis Law Report

DECEMBER 9, 2021

The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch. DENVER, Dec.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

DECEMBER 20, 2021

(“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., Media: Laura Radocaj. Chipman, CPA. Chief Financial Officer. cchipman@virpaxpharma.com 610-727-4597.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Data 52

Cannabis Law Report

JULY 24, 2019

Marketwatch report… Shares of cannabis company Curaleaf Holdings Inc. 1 We have also reviewed your social media websites at www.facebook.com/CuraleafHemp External Link Disclaimer and [link] External Link Disclaimer ; these websites direct consumers to your website, [link] External Link Disclaimer , to purchase your products.

CBD 51

CBD Tincture Pets Chronic Pain 51

Project CBD

FEBRUARY 28, 2023

The combined total from both channels — $58,293,034 — does not include CBD sales in licensed cannabis dispensaries or CBD products, such as vapes, tinctures, gummies, and other edibles sold online. (E-commerce According to the FDA, “hemp” is defined as Cannabis sativa with a tetrahydrocannabinol (THC) concentration of 0.3%

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

NOVEMBER 24, 2021

Medical publications, are, in the main fairly positive toward cannabis. Published by The Journal of Cannabis Research. Medicinal cannabis has been legalised for use for a range of specified medical conditions in Australia since 2016. At the same time, the outlook on cannabis research data is largely positive. Background.

Research and Development 52

Research and Development Medicine Access Media 52

The Cannigma

APRIL 8, 2021

Listen & Subscribe: As both a regulated medicine and something people use for wellness and even recreation, the information gaps that exist for cannabis users are unprecedented. Any other medication and you’re lawfully entitled to speak to a pharmacist,” explains Dr. Codi Peterson, a clinical pharmacist and medical cannabis professional.

Medicine 108

Medicine Cannabinoids Cannabis THC 108

Cannabis Law Report

MARCH 29, 2020

According to Vividata’s National Cannabis Consumer Study , 70% of consumers are not sure they know the difference between THC and CBD. Moreover, quality remains the top criterion in selecting a cannabis product for purchase. Setting Standards for Cannabis Research Studies . Product Quality in Manufacturing.

Compliance 69

Compliance Compliance Supply Chain Research and Development 69

Cannabis Law Report

JULY 8, 2021

Media Contacts Caitlin Kasunich / Raquel Cona KCSA Strategic Communications 212.896.1241 / 212.896.1204 ckasunich@kcsa.com / rcona@kcsa.com. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Treatment 98

Treatment Clinical Trials CBD Patients 98

CannaMD

MARCH 8, 2021

Prohibiting a qualified physician from issuing a physician certification to a minor patient for marijuana, except for low-THC cannabis [p. Authorizing the department to sample marijuana delivery devices from a dispensing facility to determine safety [p. 1, line 12]. 2, line 26]. 2, line 29]. 1, line 21]. 1, line 14]. 1, line 17].

THC 116

THC Research and Development Treatment Patients 116

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. MAPS completed the first Phase 1 safety study with MDMA and resumed working on a protocol for anxiety associated with cancer.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

DECEMBER 8, 2021

Charles River Laboratories, a renowned CRO engaged by Virpax to perform Food and Drug Administration (FDA) required pre-clinical studies, has completed a single dose pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (“IND”) enabling trials.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Topical 52

Cannabis Law Report

JULY 15, 2022

Sunshine Coast based Tikun Oceana, formerly known as Medifarm , is now under the control of administrators from Cor Cordis.The company was founded …… Predictably Murdoch media has this behind a paywall if you want to pay to learn more. Medifarm is one of just four licensed medicinal cannabis farms to gain approval in Australia.

Medicine 52

Medicine Patients Media Supply Chain 52

Cannabis Law Report

NOVEMBER 10, 2021

as well as to support Good Laboratory Practices (GLP) toxicology, safety studies and preclinical efficacy studies. The NIH has contracted with a clinical research organization to conduct additional pre-clinical efficacy studies and procured a device to be used with the manufactured GMP drug product for preclinical and clinical studies.

Research and Development 52

Research and Development Chronic Pain Pharmaceutical Clinical Trials 52

Cannabis Law Report

DECEMBER 28, 2021

Upon completion of all the required IND enabling studies and subsequent review by the FDA, Virpax intends to conduct a Phase 1 study to evaluate the relative bioavailability and pharmacokinetics of Epoladerm™ Virpax recently announced the execution of a clinical trial agreement with Altasciences Company, Inc., Chipman, CPA.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

JULY 21, 2022

Be warned, media are going bananas excited about this. Booker, Schumer, Wyden Introduce Cannabis Administration and Opportunity Act. Cannabis Administration And Opportunity Act: Text can be found HERE , Summary of introduced CAOA can be found HERE , Summary of revisions to the CAOA discussion draft can be found HERE.

Safety 52

Safety Legislation Clinical Trials Banking 52

Cannabis Law Report

JUNE 4, 2021

Our proprietary ranking system takes into account: Social reach (social media, blogs, podcasts, publications, etc.). Through his social media outlets, podcast, blog, and interviews, Tim has educated hundreds of millions of people about psychedelics. This list is focused on those who have had the largest impact for 2021. . Followers.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51

Cannabis Law Report

DECEMBER 7, 2021

Radicle Science re-imagined clinical trials resulting in 10x cheaper, faster, and larger studies that can finally prove or predict which nonprescription health products to use for a desired effect, benefiting consumers, healthcare providers and brands.”. Media Contact: Eric Schudiske ( eric@s2spr.com ).

Clinical Trials 52

Clinical Trials CBD Data Sleep 52